Augmentation of selective serotonin reuptake inhibitors with N-acetitcysteine for treatment resistant Obsessive-Compulsive Disorder: a double-blind, controlled study

• Grant number: 11/51485-9
• Support Opportunities: Regular Research Grants
• Start date: March 01, 2012
• End date: February 28, 2015
• Field of knowledge: Health Sciences - Medicine - Psychiatry
• Principal Investigator: Roseli Gedanke Shavitt
• Grantee: Roseli Gedanke Shavitt
• Host Institution: Instituto de Psiquiatria Doutor Antonio Carlos Pacheco e Silva (IPq). Hospital das Clínicas da Faculdade de Medicina da USP (HCFMUSP). Secretaria da Saúde (São Paulo - Estado). São Paulo , SP, Brazil

Abstract

Obsessive-compulsive disorder (OCD) nas a lifetime prevalence of about 3%, and is associated with significant impairment in social, occupational, academic and family settings. The selective serotonin reuptake inhibitors (SSRIs) are the first choice pharmacological treatment for OCD. However, up to a third of patients do not present satisfactory improvement with this agents. Riluzole, an anti-glutamatergic agent, has been associated with improvement in OCD symptoms after combination with SSRIs in patients previously unresponsive to SSRI monotherapy. Based on this preliminar/ result, it has been hypothesized that other anti-glutamatergic agents could potentiate the effect of SSRIs in OCD patients with a poor response to SSRI monotherapy. The main objective of this clinical trial is to investigate, using a double-blind, placebo-controlled design, the efficacy of N-acetilcysteíne (NAC), an anti-glutamatergic agent, as an augmenting agent for OCD patients unresponsive to SSRI monotherapy. The primary outcome will be the reduction of baseline Yale-Brown Obsessive-Compulsive Scale (YBOCS) scores. Forry outpatients with primary DSM-IV criteria OCD will be randomly assigned to augmentation of the SSRI with either NAC (n=20) or placebo (n=20). Our hypothesis is that NAC will be effective in reducing OCD symptoms after 16 weeks follow-up. (AU)

Scientific publications

(4)

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

DA CONCEICAO COSTA, DANIEL L.; BARBOSA, VERONICA S.; REQUENA, GUARACI; SHAVITT, ROSELI G.; PEREIRA, CARLOS A. DE BRAGANCA; DINIZ, JULIANA B.. Dissecting the Yale-Brown Obsessive-Compulsive Scale severity scale to understand the routes for symptomatic improvement in obsessive-compulsive disorder. JOURNAL OF PSYCHOPHARMACOLOGY, v. 31, n. 10, p. 1312-1322, OCT 2017. (12/14070-8, 11/51485-9)

DA CONCEICAO COSTA, DANIEL LUCAS; SHAVITT, ROSELI GEDANKE; CASTRO CESAR, RAONY CASSAB; JOAQUIM, MARINES ALVES; BORCATO, SONIA; VALERIO, CAROLINA; MIGUEL, EURIPEDES CONSTANTINO; DINIZ, JULIANA BELO. Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making. JOURNAL OF PSYCHIATRIC RESEARCH, v. 47, n. 11, p. 1700-1707, NOV 2013. (11/51485-9, 12/14070-8, 11/00968-0)

COSTA, DANIEL L. C.; DINIZ, JULIANA B.; REQUENA, GUARACI; JOAQUIM, MARINES A.; PITTENGER, CHRISTOPHER; BLOCH, MICHAEL H.; MIGUEL, EURIPEDES C.; SHAVITT, ROSELI G.. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. JOURNAL OF CLINICAL PSYCHIATRY, v. 78, n. 7, p. E766+, JUL-AUG 2017. (11/51485-9, 12/14070-8)

BATISTUZZO, MARCELO C.; HOEXTER, MARCELO Q.; TAUB, ANITA; GENTIL, ANDRE F.; CESAR, RAONY C. C.; JOAQUIM, MARINES A.; D'ALCANTE, CARINA CHAUBET; MCLAUGHLIN, NICOLE C.; CANTERAS, MIGUEL M.; SHAVITT, ROSELI G.; et al. Visuospatial Memory Improvement after Gamma Ventral Capsulotomy in Treatment Refractory Obsessive-Compulsive Disorder Patients. NEUROPSYCHOPHARMACOLOGY, v. 40, n. 8, p. 1837-1845, JUL 2015. (11/21357-9, 08/10257-0, 11/51485-9, 09/09949-8)